Pembrolizumab with etoposide and a platinum-based compound for untreated extensive-stage small-cell lung cancer [ID1509]
Discontinued
Reference number: GID-TA10413
The Department for Health and Social Care has asked NICE to conduct an appraisal of pembrolizumab with chemotherapy for untreated extensive-stage small-cell lung cancer.
Please note that following on from advice received from the company the timelines for this appraisal have been revised.
We now anticipate that the appraisal will begin during early- February 2020 when we will write to you about how you can get involved.